Overview

Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)

Status:
Withdrawn

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The primary study objective will be to assess the efficacy of the combination of radiation therapy with nimotuzumab and cisplatin, as compared to the combination of radiation therapy plus cisplatin in the treatment of Uterine Cervical Carcinoma (UCC). The secondary study objectives will be safety and tolerability evaluations, to determine treatment feasibility and the interim efficacy evaluation according to other parameters routinely used in oncology.

Phase:

Phase 2

Details

Lead Sponsor:

Eurofarma Laboratorios S.A.

Treatments:

Cisplatin
Nimotuzumab